The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis
Open accessAbstract
Background and aims: Immunosuppressive therapy with intravenous ciclosporin is an alternative treatment option to total colectomy for patients with ulcerative colitis (UC), while the benefits of oral administration of tacrolimus are not well defined and are based on reports of several uncontrolled studies. Methods: Patients with refractory active UC were randomly assigned to a high trough concentration (10–15 ng/ml) group (HT group) (n = 21), low trough concentration (5–10 ng/ml) group (LT group) (n = 22), or placebo group (n = 20). Patients received an initial oral dose of 0.05 mg/kg tacrolimus or placebo twice daily. Efficacy was evaluated in 60 patients based on a disease activity index (DAI) score. Fifty eight patients had additional treatment with tacrolimus and were evaluated for efficacy in a 10 week open label extension. Results: An improvement in DAI score (⩾4 points, all categories improved) was observed for 68.4% of cases in the HT group compared with 10.0% in the placebo group (p<0.001). In the HT group, 20.0% of patients had clinical remission and 78.9% had mucosal healing. In the open label extension, 55.2% of all patients had an improved DAI score at week 10. Mean dose of prednisolone was reduced from 19.7 mg/day at study entry to 7.8 mg/day at week 10. The incidence of side effects in the HT group was significantly higher than that of the placebo group (p = 0.043). The most common event was mild finger tremor. Conclusions: Our findings demonstrate dose dependent efficacy and safety of oral tacrolimus for remission-induction therapy of refractory UC. The optimal target range appears to be 10–15 ng/ml in terms of efficacy with two week therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026
Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy
Lichtiger, S., Present, D. H., Kornbluth, A., Gelernt, I., Bauer, J., Galler, G., Michelassi, F., & Hanauer, S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406303302601 · Cited by 1,714
KINO, T., HATANAKA, H., HASHIMOTO, M., NISHIYAMA, M., GOTO, T., OKUHARA, M., KOHSAKA, M., AOKI, H., & IMANAKA, H. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.1249 · Cited by 1,241
KINO, T., HATANAKA, H., MIYATA, S., INAMURA, N., NISHIYAMA, M., YAJIMA, T., GOTO, T., OKUHARA, M., KOHSAKA, M., AOKI, H., et al. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.1256 · Cited by 1,209
Järnerot, G., Hertervig, E., Friis-Liby, I., Blomquist, L., Karlén, P., Grännö, C., Vilien, M., Ström, M., Danielsson, Å., Verbaan, H., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.003 · Cited by 1,089
Sutherland, L. R., Martin, F., Greer, S., Robinson, M., Greenberger, N., Saibil, F., Martin, T., Sparr, J., Prokipchuk, E., & Borgen, L. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90621-4 · Cited by 677
Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study
Sands, B. E., Tremaine, W. J., Sandborn, W. J., Rutgeerts, P. J., Hanauer, S. B., Mayer, L., Targan, S. R., & Podolsky, D. K. (2001) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200105000-00001 · Cited by 422
Probert, C. S. J., Hearing, S. D., Schreiber, S., Kühbacher, T., Ghosh, S., Arnott, I. D. R., & Forbes, A. (2003) · Gut · doi:10.1136/gut.52.7.998 · Cited by 355
Sandborn, W. J., Present, D. H., Isaacs, K. L., Wolf, D. C., Greenberg, E., Hanauer, S. B., Feagan, B. G., Mayer, L., Johnson, T., Galanko, J., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00877-1 · Cited by 333
Cited by
Inflammatory bowel disease: clinical aspects and established and evolving therapies
Baumgart, D. C., & Sandborn, W. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60751-x · Cited by 1,920
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548
Harbord, M., Eliakim, R., Bettenworth, D., Karmiris, K., Katsanos, K., Kopylov, U., Kucharzik, T., Molnár, T., Raine, T., Sebastian, S., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx009 · Cited by 1,180
Khan, I., Ullah, N., Zha, L., Bai, Y., Khan, A., Zhao, T., Che, T., & Zhang, C. (2019) · Pathogens · doi:10.3390/pathogens8030126 · Cited by 771
Stange, E. F., Travis, S. P. L., Vermeire, S., Reinisch, W., Geboes, K., Barakauskiene, A., Feakins, R., Fléjou, J. F., Herfarth, H., Hommes, D. W., et al. (2008) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2007.11.001 · Cited by 555
Metadata
- Authors
- Ogata, H., Matsui, T., Nakamura, M., Iida, M., Takazoe, M., Suzuki, Y., & Hibi, T.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2006-02-16
- Volume
- 55
- Issue
- 9
- Pages
- 1255-1262
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2102804688
- Cited by
- 462
- References
- 28
- FWCI
- 13.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. https://app.cochat.ai/papers/10.1136/gut.2005.081794
- The paper
- Ogata, H., Matsui, T., Nakamura, M., Iida, M., Takazoe, M., Suzuki, Y., & Hibi, T. (2006). A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. https://doi.org/10.1136/gut.2005.081794
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
